A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or
Is Altimmune (ALT) stock a buy right now?
Categories
Biotechnology
Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Earnings Call Transcript
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q2 2020 earnings call dated Aug. 11, 2020 Corporate Participants: Glenn Schulman -- Senior Vice President, Corporate Communications and
Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2020 earnings call dated August 10, 2020 Corporate Participants: Jeff Boyle -- Senior Director of Investor Relations Jeff
Novavax Inc. (NVAX) Q2 2020 Earnings Call Transcript
Novavax Inc (NASDAQ: NVAX) Q2 2020 earnings call dated Aug. 10, 2020 Corporate Participants: Silvia Taylor -- Senior Vice President, Investor Relations and Corporate
Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views
Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to
Moderna, Inc. (MRNA) Q2 2020 Earnings Conference Call Transcript
Moderna Inc. (NASDAQ: MRNA) Q2 2020 earnings call dated Aug. 05, 2020 Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive
Moderna impresses on the financial side as well in Q2
Moderna, Inc., (Nasdaq: MRNA), a prime contender in Covid-19 vaccine research, on Wednesday, reported second-quarter financial results that smashed past analysts’ estimates.
Amarin (AMRN) Q2 2020 earnings call: Focus was mainly on VASCEPA litigation
Amarin (NASDAQ: AMRN) reported second quarter 2020 results yesterday. During the earnings conference call, the management and the analysts discussed mainly the
Immunogen Inc. (IMGN) Q2 2020 Earnings Call Transcript
Immunogen Inc (NASDAQ: IMGN) Q2 2020 earnings call dated July 31, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
ImmunoGen (IMGN) Earnings: 2Q20 Key Numbers
ImmunoGen Inc. (NASDAQ: IMGN) reported second quarter 2020 earnings results today. Revenues were $15 million, compared to $15.5 million in the prior-year period. Net loss
Vertex Pharmaceuticals Inc. (VRTX) Q2 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Michael Partridge -- Senior Vice President, Investor Relations Reshma
Gilead Sciences Inc. (GILD) Q2 2020 Earnings Call Transcript
Gilead Sciences Inc (NASDAQ: GILD) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Douglas Maffei -- Senior Director, Investor Relations Daniel O'Day -- Chairman
Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings
Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and
Amgen Inc. (AMGN) Q2 2020 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q2 2020 earnings call dated July 28, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A.
Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q2 2020 earnings call dated July 22, 2020 Corporate Participants: Joe Mara -- Vice President of Finance and Head of
Novartis International AG (NVS) Q2 2020 Earnings Call Transcript
Novartis International AG (NYSE: NVS) Q2 2020 earnings call dated Jul. 21, 2020 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant
Infographic: Key financials of Biogen (BIIB) Q2 2020 earnings report
Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted
Moderna Inc (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call Transcript
Moderna Inc (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call dated July 15, 2020 Corporate Participants: Lavina Talukdar -- Head
Moderna medical chief: Varying infection rate to be the biggest challenge in Phase 3
A diverse population with varying infection rates will be among the biggest challenges during the phase 3 trials of its COVID-19 vaccine
Avid Bioservices, Inc. (NASDAQ: CDMO) Q4 2020 Earnings Call Transcript
Avid Bioservices, Inc. (CDMO) Q4 2020 earnings call dated June 30, 2020 Corporate Participants: Tim Brons -- Executive Vice President Rick Hancock -- Interim President and